SG11202005296SA - Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer - Google Patents
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancerInfo
- Publication number
- SG11202005296SA SG11202005296SA SG11202005296SA SG11202005296SA SG11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA
- Authority
- SG
- Singapore
- Prior art keywords
- immunotherapy
- combination therapy
- treat cancer
- progastrin antibody
- progastrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762594755P | 2017-12-05 | 2017-12-05 | |
PCT/EP2018/083651 WO2019110662A1 (en) | 2017-12-05 | 2018-12-05 | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005296SA true SG11202005296SA (en) | 2020-07-29 |
Family
ID=64949216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005296SA SG11202005296SA (en) | 2017-12-05 | 2018-12-05 | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
Country Status (14)
Country | Link |
---|---|
US (2) | US11046758B2 (ja) |
EP (1) | EP3720879B1 (ja) |
JP (1) | JP7104153B2 (ja) |
KR (1) | KR102461238B1 (ja) |
CN (1) | CN111670197A (ja) |
AU (1) | AU2018379320B2 (ja) |
CA (1) | CA3084687C (ja) |
DK (1) | DK3720879T3 (ja) |
ES (1) | ES2920283T3 (ja) |
PL (1) | PL3720879T3 (ja) |
PT (1) | PT3720879T (ja) |
SG (1) | SG11202005296SA (ja) |
TW (1) | TWI763956B (ja) |
WO (1) | WO2019110662A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3720879T3 (pl) * | 2017-12-05 | 2022-09-12 | Progastrine Et Cancers S.À R.L. | Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu |
CN112368579B (zh) * | 2018-02-27 | 2024-05-03 | Ecs前胃泌素股份有限公司 | 作为生物标记物的前胃泌素用于免疫疗法 |
CN111171146B (zh) * | 2020-02-20 | 2022-03-04 | 西北农林科技大学 | 抗h9n2亚型禽流感病毒的纳米抗体、制备方法和应用 |
CN115466328A (zh) * | 2021-06-11 | 2022-12-13 | 广东菲鹏制药股份有限公司 | 抗pd-1人源化抗体或其抗原结合片段及其应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5546806A (en) | 1991-10-17 | 1996-08-20 | Kain; Aron Z. | Microwave vector displacement and acceleration transducer |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5474896A (en) | 1992-05-05 | 1995-12-12 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DK1427828T3 (da) | 2001-09-14 | 2010-07-19 | Cellectis | Tilfældig integration af et polynucleotid efter in vivo-linearisering |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
WO2004067753A2 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
ES2400058T3 (es) | 2004-09-22 | 2013-04-05 | Cancer Advances, Inc. | Anticuerpos monoclonales para progastrina |
US8936936B2 (en) | 2007-10-25 | 2015-01-20 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
LT2488551T (lt) * | 2009-10-16 | 2018-10-25 | Progastrine Et Cancers S.A R.L. | Monokloniniai antikūnai prieš progastriną ir jų panaudojimas |
US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
US9487582B2 (en) * | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
JP5829672B2 (ja) * | 2010-03-24 | 2015-12-09 | レ ラボラトワール セルヴィエ | 結腸直腸及び胃腸癌の予防 |
AU2011284908B2 (en) * | 2010-07-26 | 2015-05-21 | Centre National De La Recherche Scientifique (Cnrs) | Methods and compositions for liver cancer therapy |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
AU2015339306B2 (en) * | 2014-10-29 | 2021-07-22 | Bristol-Myers Squibb Company | Combination therapy for cancer |
KR102428254B1 (ko) * | 2015-12-31 | 2022-08-03 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 난소암의 검출 및 치료를 위한 조성물 및 방법 |
US20190011449A1 (en) * | 2015-12-31 | 2019-01-10 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating gastric cancer |
PL3397967T3 (pl) * | 2015-12-31 | 2021-06-28 | Progastrine Et Cancers S.À R.L. | Kompozycje i sposoby do wykrywania i leczenia raka przełyku |
EP3601343B1 (en) * | 2017-03-30 | 2022-05-04 | ECS-Progastrin SA | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
CA3058270C (en) * | 2017-03-30 | 2023-07-18 | Ecs-Progastrin Sa | Compositions and methods for detecting lung cancer |
EP3624841A4 (en) * | 2017-06-15 | 2021-01-27 | Cancer Advances, Inc., | COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER |
PL3720879T3 (pl) * | 2017-12-05 | 2022-09-12 | Progastrine Et Cancers S.À R.L. | Terapia skojarzona przeciwciałami przeciwko progastynie i immunoterapią w leczeniu nowotworu |
CN112368579B (zh) * | 2018-02-27 | 2024-05-03 | Ecs前胃泌素股份有限公司 | 作为生物标记物的前胃泌素用于免疫疗法 |
-
2018
- 2018-12-05 PL PL18829742.8T patent/PL3720879T3/pl unknown
- 2018-12-05 WO PCT/EP2018/083651 patent/WO2019110662A1/en active Application Filing
- 2018-12-05 CN CN201880088139.2A patent/CN111670197A/zh active Pending
- 2018-12-05 DK DK18829742.8T patent/DK3720879T3/da active
- 2018-12-05 ES ES18829742T patent/ES2920283T3/es active Active
- 2018-12-05 CA CA3084687A patent/CA3084687C/en active Active
- 2018-12-05 PT PT188297428T patent/PT3720879T/pt unknown
- 2018-12-05 JP JP2020530573A patent/JP7104153B2/ja active Active
- 2018-12-05 KR KR1020207019218A patent/KR102461238B1/ko active IP Right Grant
- 2018-12-05 US US16/769,844 patent/US11046758B2/en active Active
- 2018-12-05 EP EP18829742.8A patent/EP3720879B1/en active Active
- 2018-12-05 SG SG11202005296SA patent/SG11202005296SA/en unknown
- 2018-12-05 AU AU2018379320A patent/AU2018379320B2/en active Active
- 2018-12-05 TW TW107143746A patent/TWI763956B/zh active
-
2021
- 2021-06-25 US US17/358,480 patent/US20210324069A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019110662A1 (en) | 2019-06-13 |
PL3720879T3 (pl) | 2022-09-12 |
JP7104153B2 (ja) | 2022-07-20 |
AU2018379320A1 (en) | 2020-07-02 |
JP2021505576A (ja) | 2021-02-18 |
KR20200118409A (ko) | 2020-10-15 |
DK3720879T3 (da) | 2022-06-20 |
US11046758B2 (en) | 2021-06-29 |
PT3720879T (pt) | 2022-07-13 |
CA3084687A1 (en) | 2019-06-13 |
EP3720879B1 (en) | 2022-05-11 |
TW201927805A (zh) | 2019-07-16 |
AU2018379320B2 (en) | 2023-06-15 |
RU2020121176A3 (ja) | 2022-04-27 |
RU2020121176A (ru) | 2022-01-10 |
ES2920283T3 (es) | 2022-08-02 |
CA3084687C (en) | 2024-01-02 |
US20210009680A1 (en) | 2021-01-14 |
KR102461238B1 (ko) | 2022-11-01 |
US20210324069A1 (en) | 2021-10-21 |
EP3720879A1 (en) | 2020-10-14 |
TWI763956B (zh) | 2022-05-11 |
CN111670197A (zh) | 2020-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
IL262562A (en) | Combination of anti-pd-1 antibodies and radiation for cancer therapy | |
IL268138A (en) | Combinations of cabozantinib and atezolizumab for cancer treatment | |
IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
IL270511A (en) | Combined treatments using niraparib and pembrolizumab for the treatment of cancer | |
HK1247630A1 (zh) | 用於增强癌症治療的效果的組合物和方法 | |
HRP20190888T8 (hr) | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
IL248704A0 (en) | Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2 | |
IL275517A (en) | Combined methods and treatment of cancer | |
SG11201707949XA (en) | Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy | |
IL275913A (en) | Methods and combined treatment for cancer treatment | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
IL274866A (en) | Preparations and methods for the treatment of cancer | |
GB201717004D0 (en) | Methods of cancer therapy | |
GB201711769D0 (en) | Methods of cancer therapy | |
GB201416605D0 (en) | Combination therapy to reduce the risk of and to treat cancer |